Adaptimmune Therapeutics PLC Sustainability Reports

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The company leverages its proprietary T-cell receptor platform to design and engineer personalized medicines targeting solid tumor cancers.

Sector: Professional & technical services

Country: United Kingdom

Exchange: Nasdaq

LEI: 549300UUNWK8TRT5EW12

FIGI: BBG008G65WD1

7 reports from 2015 to 2024

• Adaptimmune Therapeutics PLC 2024 Form 10-K
• Adaptimmune Therapeutics PLC 2023 Annual Report and Financial Statements
• Adaptimmune Therapeutics PLC 2022 Annual Report and Financial Statements
• Adaptimmune Therapeutics PLC 2021 Annual Report and Financial Statements
• Adaptimmune Therapeutics PLC 2018 Annual Report and Financial Statements